Trial Profile
A 52-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 24 Nov 2021
Price :
$35
*
At a glance
- Drugs Relamorelin (Primary)
- Indications Diabetic gastroparesis
- Focus Adverse reactions; Pharmacodynamics; Registrational; Therapeutic Use
- Sponsors AbbVie; Allergan
- 16 Dec 2020 This trial has been completed in Denmark (Date of the global end of the trial: 05 Nov 2020).
- 26 Nov 2020 This trial has been completed in Hungary according to European Clinical Trials Database record.
- 06 Oct 2020 Status changed from active, no longer recruiting to discontinued.